- Home
- OBE vs ATYR Comparison
OBE vs ATYR Comparison
Compare OBE & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBE
- ATYR
- Stock Information
- Founded
- OBE 1979
- ATYR 2005
- Country
- OBE Canada
- ATYR United States
- Employees
- OBE N/A
- ATYR N/A
- Industry
- OBE Oil & Gas Production
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OBE Energy
- ATYR Health Care
- Exchange
- OBE Nasdaq
- ATYR Nasdaq
- Market Cap
- OBE 411.1M
- ATYR 451.3M
- IPO Year
- OBE N/A
- ATYR 2015
- Fundamental
- Price
- OBE $6.12
- ATYR $4.72
- Analyst Decision
- OBE Buy
- ATYR Strong Buy
- Analyst Count
- OBE 2
- ATYR 6
- Target Price
- OBE $11.50
- ATYR $20.20
- AVG Volume (30 Days)
- OBE 337.5K
- ATYR 5.9M
- Earning Date
- OBE 07-30-2025
- ATYR 08-12-2025
- Dividend Yield
- OBE N/A
- ATYR N/A
- EPS Growth
- OBE N/A
- ATYR N/A
- EPS
- OBE N/A
- ATYR N/A
- Revenue
- OBE $501,517,751.00
- ATYR N/A
- Revenue This Year
- OBE N/A
- ATYR $551.06
- Revenue Next Year
- OBE $2.15
- ATYR $1,874.58
- P/E Ratio
- OBE N/A
- ATYR N/A
- Revenue Growth
- OBE N/A
- ATYR N/A
- 52 Week Low
- OBE $3.88
- ATYR $1.67
- 52 Week High
- OBE $7.50
- ATYR $7.29
- Technical
- Relative Strength Index (RSI)
- OBE 61.94
- ATYR 42.73
- Support Level
- OBE $5.89
- ATYR $5.46
- Resistance Level
- OBE $6.37
- ATYR $7.29
- Average True Range (ATR)
- OBE 0.22
- ATYR 0.65
- MACD
- OBE 0.05
- ATYR -0.13
- Stochastic Oscillator
- OBE 67.06
- ATYR 2.66
About OBE Obsidian Energy Ltd.
Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Crude oil sale.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.